MRTX1133's Promise for Treating KRAS-mutant Pancreatic Cancer

Overview

Journal J Gastrointest Oncol

Date 2024 Sep 16

PMID 39279949

Authors

Malak Haidar

Patrick Jacquemin

Affiliations

Soon will be listed here.

References

Halbrook C, Lyssiotis C, Pasca di Magliano M, Maitra A . Pancreatic cancer: Advances and challenges. Cell. 2023; 186(8):1729-1754. PMC: 10182830. DOI: 10.1016/j.cell.2023.02.014. View

Vigil D, Cherfils J, Rossman K, Der C . Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?. Nat Rev Cancer. 2010; 10(12):842-57. PMC: 3124093. DOI: 10.1038/nrc2960. View

Hong D, Fakih M, Strickler J, Desai J, Durm G, Shapiro G . KRAS Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med. 2020; 383(13):1207-1217. PMC: 7571518. DOI: 10.1056/NEJMoa1917239. View

Cox A, Fesik S, Kimmelman A, Luo J, Der C . Drugging the undruggable RAS: Mission possible?. Nat Rev Drug Discov. 2014; 13(11):828-51. PMC: 4355017. DOI: 10.1038/nrd4389. View

Bailey P, Chang D, Nones K, Johns A, Patch A, Gingras M . Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016; 531(7592):47-52. DOI: 10.1038/nature16965. View

Mahadevan K, McAndrews K, LeBleu V, Yang S, Lyu H, Li B . KRAS inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8 T cells. Cancer Cell. 2023; 41(9):1606-1620.e8. PMC: 10785700. DOI: 10.1016/j.ccell.2023.07.002. View

Welsch M, Kaplan A, Chambers J, Stokes M, Bos P, Zask A . Multivalent Small-Molecule Pan-RAS Inhibitors. Cell. 2017; 168(5):878-889.e29. PMC: 5362268. DOI: 10.1016/j.cell.2017.02.006. View

Gulay K, Zhang X, Pantazopoulou V, Patel J, Esparza E, Sheik Pran Babu D . Dual Inhibition of KRASG12D and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma. Cancer Res. 2023; 83(18):3001-3012. PMC: 10502451. DOI: 10.1158/0008-5472.CAN-23-1313. View

Wei D, Wang L, Zuo X, Maitra A, Bresalier R . A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer. Clin Cancer Res. 2023; 30(4):655-662. PMC: 10922474. DOI: 10.1158/1078-0432.CCR-23-2098. View

10.

Ushio J, Kanno A, Ikeda E, Ando K, Nagai H, Miwata T . Pancreatic Ductal Adenocarcinoma: Epidemiology and Risk Factors. Diagnostics (Basel). 2021; 11(3). PMC: 8003883. DOI: 10.3390/diagnostics11030562. View

11.

Ostrem J, Peters U, Sos M, Wells J, Shokat K . K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013; 503(7477):548-51. PMC: 4274051. DOI: 10.1038/nature12796. View

12.

Leshchiner E, Parkhitko A, Bird G, Luccarelli J, Bellairs J, Escudero S . Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices. Proc Natl Acad Sci U S A. 2015; 112(6):1761-6. PMC: 4330742. DOI: 10.1073/pnas.1413185112. View

13.

Linehan A, OReilly M, McDermott R, OKane G . Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies. Front Med (Lausanne). 2024; 11:1369136. PMC: 10991798. DOI: 10.3389/fmed.2024.1369136. View

14.

Payne S, Maher M, Tran N, Van De Hey D, Foley T, Yueh A . PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors. Oncogenesis. 2015; 4:e169. PMC: 4632089. DOI: 10.1038/oncsis.2015.28. View

15.

Engstrom L, Aranda R, Waters L, Moya K, Bowcut V, Vegar L . MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer. Cancer Discov. 2023; 13(11):2412-2431. PMC: 10618744. DOI: 10.1158/2159-8290.CD-23-0669. View

16.

Wang X, Allen S, Blake J, Bowcut V, Briere D, Calinisan A . Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS Inhibitor. J Med Chem. 2021; 65(4):3123-3133. DOI: 10.1021/acs.jmedchem.1c01688. View

17.

Janes M, Zhang J, Li L, Hansen R, Peters U, Guo X . Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. Cell. 2018; 172(3):578-589.e17. DOI: 10.1016/j.cell.2018.01.006. View

18.

Kolch W, Berta D, Rosta E . Dynamic regulation of RAS and RAS signaling. Biochem J. 2023; 480(1):1-23. PMC: 9988006. DOI: 10.1042/BCJ20220234. View

19.

Ho W, Jaffee E, Zheng L . The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities. Nat Rev Clin Oncol. 2020; 17(9):527-540. PMC: 7442729. DOI: 10.1038/s41571-020-0363-5. View

20.

Aung K, McWhirter E, Welch S, Wang L, Lovell S, Stayner L . A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma. J Gastrointest Oncol. 2023; 13(6):3216-3226. PMC: 9830369. DOI: 10.21037/jgo-22-86. View